Cadigan R Jean, Edwards Teresa P, Lassiter Dragana, Davis Arlene M, Henderson Gail E
1 Department of Social Medicine, CB 7240, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina.
2 HW Odum Institute for Research in Social Science, CB 3355, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina.
Genet Test Mol Biomarkers. 2017 Mar;21(3):148-154. doi: 10.1089/gtmb.2016.0393. Epub 2017 Jan 24.
Do biobanks enact policies and plans that allow them to anticipate and respond to potential challenges? If a biobank has one such policy or plan, is it likely to have more? Using survey data from 456 U.S. biobanks, we assess four possible indicators of such "forward-thinking."
We present response frequencies and cross-tabulations regarding policies for return of results and ownership of specimens, and for having a formal business plan and a plan for what happens to specimens if the biobank closes. We analyze the relationships among these indicators, using chi-square for tests of statistical significance.
Policies-Sixty-two percent of biobanks have a policy about returning individual research results; 70% have a policy designating ownership of specimens and/or technology. Having these two policies is significantly related (p < 0.001). Plans-34% of biobanks have a formal business plan; 26% have a written plan for what will happen to the specimens if the biobank closes. Having these two plans is significantly related (p < 0.001). Relationships among indicators-only 7% of biobanks are forward-thinking across all four indicators; 12% are forward-thinking across none.
The two policies we examined tend to occur together, as do the two plans. These policies and plans seem to tap different aspects of accountability and responsiveness. Specifically, the policies reflect issues most commonly raised in the ethical and legal literature on biobanking, while the plans are indicators of sustainability, a separate area of concern in biobanking.
生物样本库是否制定了能够使其预见并应对潜在挑战的政策和计划?如果一个生物样本库有一项这样的政策或计划,它是否更有可能有更多此类政策或计划?利用来自456个美国生物样本库的调查数据,我们评估了这种“前瞻性思维”的四个可能指标。
我们呈现了关于结果返还政策、样本所有权政策、拥有正式商业计划以及生物样本库关闭时样本处置计划的应答频率和交叉制表。我们使用卡方检验分析这些指标之间的关系,以检验统计显著性。
政策——62%的生物样本库有关于返还个体研究结果的政策;70%有指定样本和/或技术所有权的政策。拥有这两项政策显著相关(p < 0.001)。计划——34%的生物样本库有正式商业计划;26%有生物样本库关闭时样本处置的书面计划。拥有这两项计划显著相关(p < 0.001)。指标之间的关系——只有7%的生物样本库在所有四个指标上都具有前瞻性思维;12%在所有指标上都没有前瞻性思维。
我们研究的两项政策往往同时出现,两项计划也是如此。这些政策和计划似乎涉及问责制和响应能力的不同方面。具体而言,政策反映了生物样本库伦理和法律文献中最常提出的问题,而计划是可持续性的指标,这是生物样本库中另一个受关注的领域。